Table 4.
Regression analyses of outpatient primary outcomes.a
|
|
Compliance, % (n/N) | Model 1 | Model 2 | Model 3 | |||||||||||||
|
|
|
ORb (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||||||||||
| N1c (N=15,714) | |||||||||||||||||
|
|
Age | N/Ad | 0.978 (0.975-0.980) | <.001 | 0.978 (0.975-0.980) | <.001 | 0.978 (0.975-0.980) | <.001 | |||||||||
|
|
Control group | 80.4 (7606/9456) | Refe | N/A | Ref | N/A | Ref | N/A | |||||||||
|
|
Intervention group | 90.2 (5643/6258) | 1.343 (1.155-1.562) | <.001 | 1.198 (0.997-1.438) | .05 | 0.999 (0.806-1.238) | .99 | |||||||||
|
|
Number of teleconsultations | —f | — | — | 1.007 (1.001-1.013) | .03 | 1.032 (1.015-1.049) | <.001 | |||||||||
|
|
Squared number of teleconsultations | — | — | — | — | — | 0.9998 (0.9996-0.9999) | .001 | |||||||||
| N2g (N=752) | |||||||||||||||||
|
|
Age | N/A | 0.996 (0.983-1.010) | .55 | 0.999 (0.985-1.012) | .83 | 0.999 (0.985-1.012) | .84 | |||||||||
|
|
Control group | 54.5 (145/266) | Ref | N/A | Ref | N/A | Ref | N/A | |||||||||
|
|
Intervention group | 75.9 (369/486) | 9.312 (3.794-25.936) | <.001 | 0.147 (0.010-1.218) | .11 | 0.092 (0.002-2.639) | .16 | |||||||||
|
|
Number of teleconsultations | — | — | — | 1.533 (1.212-2.190) | .004 | 1.717 (0.819-3.174) | .08 | |||||||||
|
|
Squared number of teleconsultations | — | — | — | — | — | 0.994 (0.978-1.038) | .65 | |||||||||
aEach model also controlled for physician-specific effects, which are not reported individually in this table; CIs were calculated based on profile likelihood estimation.
bOR: odds ratio.
cPrimary outcome N1: Avoid prescribing antibiotics for uncomplicated upper respiratory tract infections.
dN/A: not applicable.
eRef reference group.
fDue to the different model specification, the respective variables were not included in all models.
gPrimary outcome N2: Do not treat asymptomatic bacteriuria with antibiotics.